Article: Genmab, Serono Sign Potential $215M Deal For HuMax-CD4.

Article from:
BIOWORLD Today
Article date:
November 3, 2009
Copyright

Staff Writer

A few months after partnering a preclinical program with Serono SA, antibody development company Genmab A/S entered a potential $215 million deal with the Swiss biotech firm involving its Phase III candidate to treat cutaneous T-cell lymphoma.

Copenhagen, Denmark-based Genmab granted Serono exclusive worldwide rights to develop and commercialize HuMax-CD4, a fully human monoclonal antibody that was granted fast-track status by the FDA and designated as an orphan drug in both the U.S. and Europe.

This deal "is really important in terms of maximizing the value of HuMax-CD4," said Genmab CEO Lisa Drakeman. "And it will allow us to ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Genmab Announces HuMax-CD32b Pre-Clinical Program.
PR Newswire Europe;  January 4, 2008 ;     700+ words ... ... Pre-clinical Antibody Program Called HuMax-CD32b. Genmab A/S (OMX: GEN) announced today a ... results, unless this is required by law. Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20 ...

Article: GENMAB STOPPING PHASE II, III TRIALS OF ...
BIOWORLD Today;  September 26, 2002 ;     700+ words ... ... 20 treated with HuMax-CD4. Genmab, based in Copenhagen ... methotrexate." Genmab had planned to file for FDA approval of HuMax CD4 in RA=20 in ... 20 company said. Genmab was granted North American rights to=20 HuMax-CD4 by Princeton ...

Article: Genmab Stopping Phase II, III Trials Of HuMax-CD4 ...
BIOWORLD Today;  November 4, 2009 ;     700+ words ... ... those treated with HuMax-CD4. Genmab, based in Copenhagen ... methotrexate." Genmab had planned to file for FDA approval of HuMax CD4 in RA in early ... the company said. Genmab was granted North American rights to HuMax-CD4 by Princeton ...

Article: GlaxoSmithKline and Genmab Enter Global Agreement For ...
PR Newswire;  December 19, 2006 ;     700+ words ... ... developed in collaboration with Genmab. GSK and Genmab will co-develop HuMax- CD20. Genmab will be responsible for development costs ... the manufacturing and commercialization of HuMax-CD20. Genmab will have an option to co-promote HuMax ...

Article: Genmab files CTA for HuMax-EGFr to treat cancer.
PR Newswire;  June 27, 2003 ;     700+ words ... ... clinical trial using HuMax-EGFr to treat head and neck cancer Genmab A/S announced today ... assess the efficacy of HuMax-EGFr. Genmab will work with the ... presented in February by Genmab showed that HuMax-EGFr effectively ...

Article: Genmab Files CTA for HuMax-EGFr to Treat Cancer; ...
PR Newswire;  June 27, 2003 ;     700+ words ... ... endpoint to assess the efficacy of HuMax-EGFr. Genmab will work with the DAHANCA group ... mouse studies have shown that HuMax-EGFr is capable of inhibiting ... Data presented in February by Genmab showed that HuMax-EGFr effectively engages immune ...

Article: Genmab, Serono Sign Potential $215M Deal For ...
BIOWORLD Today;  August 19, 2005 ;     700+ words ... ... maximizing the value of HuMax-CD4," said Genmab CEO Lisa Drakeman ... appears only on T cells. Genmab secured all the rights to HuMax-CD4 in late June ... based Amgen Inc., Genmab is developing AMG 714, formerly HuMax-IL15, which is in ...

Article: Genmab Regains Rights to HuMax-TAC.
PR Newswire Europe;  August 2, 2007 ;     700+ words ... ... Regaining the rights to HuMax-TAC will not influence Genmab's financial guidance ... regained rights to the HuMax-TAC program, Genmab will review the program ... R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4 ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives